Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Rawrasauruson Aug 18, 2021 2:35pm
123 Views
Post# 33724563

RE:RE:RE:RE:RE:RE:RE:Sad

RE:RE:RE:RE:RE:RE:RE:Sad

Rar. Seriously, you don't know what you are talking about. Let the adults talk.

1. - Regarding your claim that Tylenonl, advil, aleve etc won't cause that? 

Advil - Ibprofen -https://www.ncbi.nlm.nih.gov/books/NBK547845/

Women develops ALT of 2000+ 10 days after dosing Ibprofen 3x daily.

Tylenol - https://www.ncbi.nlm.nih.gov/books/NBK548162/
3x increase in ALT in 39% of patients all the way up to 2000+ ALT.

Aleve - Naproxen https://www.ncbi.nlm.nih.gov/books/NBK548159/ 
See case report 1 where a women developed 500+ ten days after dosing 500 mg of Naproxen ( aleve)

2. Again, you are wrong. It's pretty much in alignment with undiagnosed fatty liver disease and complications from every other NSAID on the market. Stop making stuff up when you clearly don't have the background in healthcare for this conversation.

 

<< Previous
Bullboard Posts
Next >>